Clal Biotechnology (Israel) Performance
| CBI Stock | 37.80 1.40 3.85% |
The firm shows a Beta (market volatility) of 0.0521, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Clal Biotechnology's returns are expected to increase less than the market. However, during the bear market, the loss of holding Clal Biotechnology is expected to be smaller as well. At this point, Clal Biotechnology has a negative expected return of -0.0983%. Please make sure to confirm Clal Biotechnology's maximum drawdown, rate of daily change, and the relationship between the jensen alpha and kurtosis , to decide if Clal Biotechnology performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Clal Biotechnology Industries has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong forward indicators, Clal Biotechnology is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 68.2 M | |
| Total Cashflows From Investing Activities | 79.2 M | |
| Free Cash Flow | -42.9 M |
Clal |
Clal Biotechnology Relative Risk vs. Return Landscape
If you would invest 4,030 in Clal Biotechnology Industries on August 29, 2024 and sell it today you would lose (250.00) from holding Clal Biotechnology Industries or give up 6.2% of portfolio value over 90 days. Clal Biotechnology Industries is producing return of less than zero assuming 2.9835% volatility of returns over the 90 days investment horizon. Simply put, 26% of all stocks have less volatile historical return distribution than Clal Biotechnology, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Clal Biotechnology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Clal Biotechnology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Clal Biotechnology Industries, and traders can use it to determine the average amount a Clal Biotechnology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0329
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CBI |
Estimated Market Risk
| 2.98 actual daily | 26 74% of assets are more volatile |
Expected Return
| -0.1 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Clal Biotechnology is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Clal Biotechnology by adding Clal Biotechnology to a well-diversified portfolio.
Clal Biotechnology Fundamentals Growth
Clal Stock prices reflect investors' perceptions of the future prospects and financial health of Clal Biotechnology, and Clal Biotechnology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Clal Stock performance.
| Return On Equity | -0.45 | |||
| Return On Asset | -0.12 | |||
| Profit Margin | (1.14) % | |||
| Operating Margin | (0.86) % | |||
| Current Valuation | 89.12 M | |||
| Shares Outstanding | 156.85 M | |||
| Price To Earning | (218.28) X | |||
| Price To Book | 0.68 X | |||
| Price To Sales | 2.79 X | |||
| Revenue | 76.96 M | |||
| EBITDA | (98.18 M) | |||
| Cash And Equivalents | 94.71 M | |||
| Cash Per Share | 0.59 X | |||
| Total Debt | 52.28 M | |||
| Debt To Equity | 6.30 % | |||
| Book Value Per Share | 0.84 X | |||
| Cash Flow From Operations | (41.33 M) | |||
| Earnings Per Share | (0.57) X | |||
| Total Asset | 444.92 M | |||
| Retained Earnings | (823 M) | |||
| Current Asset | 254 M | |||
| Current Liabilities | 61 M | |||
About Clal Biotechnology Performance
By analyzing Clal Biotechnology's fundamental ratios, stakeholders can gain valuable insights into Clal Biotechnology's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Clal Biotechnology has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Clal Biotechnology has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Clal Biotechnology Industries Ltd. is a private equity and venture capital firm specializing in development stage, pre-clinical incubation, seed, start-up, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing. It operates as a subsidiary of Clal Industries and Investments Ltd. CLAL BIOTECHNOLOGY operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange.Things to note about Clal Biotechnology performance evaluation
Checking the ongoing alerts about Clal Biotechnology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Clal Biotechnology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Clal Biotechnology generated a negative expected return over the last 90 days | |
| Clal Biotechnology has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 76.96 M. Net Loss for the year was (89.58 M) with profit before overhead, payroll, taxes, and interest of 10.72 M. | |
| Clal Biotechnology Industries has accumulated about 94.71 M in cash with (41.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.59. | |
| Roughly 65.0% of the company shares are held by company insiders |
- Analyzing Clal Biotechnology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Clal Biotechnology's stock is overvalued or undervalued compared to its peers.
- Examining Clal Biotechnology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Clal Biotechnology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Clal Biotechnology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Clal Biotechnology's stock. These opinions can provide insight into Clal Biotechnology's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Clal Stock analysis
When running Clal Biotechnology's price analysis, check to measure Clal Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clal Biotechnology is operating at the current time. Most of Clal Biotechnology's value examination focuses on studying past and present price action to predict the probability of Clal Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clal Biotechnology's price. Additionally, you may evaluate how the addition of Clal Biotechnology to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |